TY  - JOUR 
AU  - Puente, Javier
AU  - González-del-Alba, Aránzazu
AU  - Sala-González, Núria
AU  - Méndez Vidal, María José
AU  - Pinto, Alvaro
AU  - Rodríguez, Ángel
AU  - Cuevas Sanz, José Miguel
AU  - Muñoz del Toro, Jacobo Rodrigo
AU  - Useros Rodríguez, Eduardo
AU  - García García-Porrero, Ángela
AU  - Vázquez Estévez, Sergio
PY  - 2019
SN  - 1471-2407
UR  - http://hdl.handle.net/20.500.11940/16079
AB  - BACKGROUND: To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to...
LA  - eng
KW  - Proportional Hazards Models
KW  - Multivariate Analysis
KW  - Middle Aged
KW  - Anemia
KW  - Prostatic Neoplasms
KW  - Adenocarcinoma
KW  - Pain
KW  - Taxoids
KW  - L-Lactate Dehydrogenase
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Antineoplastic Agents
KW  - Humans
KW  - Treatment Outcome
KW  - Prospective Studies
KW  - Kaplan-Meier Estimate
KW  - Asthenia
KW  - Prednisone
KW  - Aged
TI  - Efficacy and Safety of Abiraterone Acetate Plus Prednisone vs. Cabazitaxel as a Subsequent Treatment After First-Line Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Results From a Prospective Observational Study (CAPRO)
DO  - 10.1186/s12885-019-5974-9
T2  - BMC CANCER
M2  - 766.0
KW  - HULA
VL  - 19
ER  -